Publications de l'intergroupe ORL

ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A; Lancet Healthy Longev. 2024 Mar;5(3):e182-e193. doi: 10.1016/S2666-7568(23)00284-2. PMID: 38432247.
Lien PubMed

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. Jerome Fayette, Claire Cropet, Julien Gautier, Clemence Toullec, Mickael Burgy, Amandine Bruyas, Christian Sire, Aurelie Lagrange, Florian Clatot, Benoit Calderon, Marie Vinches, Mariana Iacob, Laurent Martin, Eve Marie Neidhardt Berard, Marie-Christine Kaminsky, Damien Vansteene, Sébastien Salas
ASCO 2023

OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial J. Thariat, M. Bosset, A. Falcoz, D. Vernerey, Y. Pointreau, S. Racadot, J.C. Faivre, J. Castelli, S. Guihard, F. Huguet, S. Chapet, Y. Tao, J. Bourhis, X.S. Sun
ESMO 2023

Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell Carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1) J. Guerlain, N. Cozic, A. Daste, O. Malard, J. Fayette, F. Rolland, O. Mauvais, A.C. Johnson, S. Salas, M. Vinches, A. Bozec, S. Vergez, E. de Monès, I. Breuskin, M. Iacob, B. Archambaud, F. Janot, C. Even
ESMO 2023

Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial K.Saleh
ESMO 2023

NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08) Fayette J, Even C, Digue L, et al BMJ Oncology 2023;2:e000065. doi: 10.1136/bmjonc-2023-000065 
Lien BMJ Oncology

Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial. Biau J, Lopez L, Thivat E, Casile M, Millardet C, Saroul N, Pham-Dang N, Molnar I, Bourhis J, Lapeyre M. Clin Transl Radiat Oncol. 2022 Nov 14;38:169-174. doi: 10.1016/j.ctro.2022.11.007. PMID: 36466746; PMCID: PMC9712819.
Lien PubMed

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial. Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. PMID: 36796234.
Lien PubMed

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. PMID: 36522816.
Lien PubMed

Do practitioners assess sinonasal adenocarcinoma extension similarly? Interdisciplinary concordance in 21 cases. Fierens S, Moya-Plana A, Vergez S, Bénard A, Gallard R, Molinier-Blossier S, Castain C, Orsel S, Verillaud B, Mortuaire G, de Gabory L. Clin Otolaryngol. 2021 May;46(3):665-669.
Lien PubMed

Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary. Tao Y, Sun XS, Pointreau Y, Tourneau CL, Sire C, Gollmer K, Crompton P, Bourhis J. Future Oncol. 2023 Aug;19(26):1769-1776. doi: 10.2217/fon-2023-0322. Epub 2023 Jul 13. PMID: 37439181.
Lien PubMed

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. Tran BT, Gelin A, Durand S, Texier M, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C. Oncoimmunology. 2022 Dec 17;12(1):2150472. doi: 10.1080/2162402X.2022.2150472. PMID: 36545254; PMCID: PMC9762837.
Lien PubMed

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Future Oncol. 2022 May;18(14):1669-1678. doi: 10.2217/fon-2021-1634. Epub 2022 Feb 17. PMID: 35172587.
Lien PubMed

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. PMID: 33684370.
Lien PubMed

A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients. N Khalladi , C Dejean , M Bosset , Y Pointreau , R Kinj , S Racadot , J Castelli , F Huguet , S Renard , S Guihard , Y Tao, J M Rouvier, A Johnson , J Bourhis , S Xu Shan, J Thariat Cancer Radiother. 2021 Dec;25(8):755-762.
Lien PubMed

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Grégoire Marret, Nicolas Isambert, Keyvan Rezai, Jocelyn Gal, Esma Saada-Bouzid, Frédéric Rolland, Maggy Chausson, Edith Borcoman, Marie Alt, Jerzy Klijanienko, Damien Vansteene, Joël Guigay, Maud Kamal, Ivan Bièche, Christophe Le Tourneau, UNICANCER Head, Neck Group. Invest New Drugs. 2021 Dec;39(6):1641-1648. doi: 10.1007/s10637-021-01152-z.
Lien PubMed

Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases. Dahan LS, Giorgi R, Vergez S, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Garrel R, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Moya-Plana A, Even C, Radulesco T, Michel J, Baujat B, Fakhry N; REFCOR members. Eur J Surg Oncol. 2021 Jun;47(6):1376-1383.
Lien PubMed

Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. Carsuzaa F, Lapeyre M, Gregoire V, Maingon P, Beddok A, Marcy PY, Salleron J, Coutte A, Racadot S, Pointreau Y, Graff P, Beadle B, Benezery K, Biau J, Calugaru V, Castelli J, Chua M, Di Rito A, Dore M, Ghadjar P, Huguet F, Jardel P, Johansen J, Kimple R, Krengli M, Laskar S, Mcdowell L, Nichols A, Tribius S, Valduvieco I, Hu C, Liem X, Moya-Plana A, D'onofrio I, Parvathaneni U, Takiar V, Orlandi E, Psyrri A, Shenouda G, Sher D, Steuer C, Shan Sun X, Tao Y, Thomson D, Tsai MH, Vulquin N, Gorphe P, Mehanna H, Yom SS, Bourhis J, Thariat J. Radiother Oncol. 2021 May 11;160:140-147. doi: 10.1016/j.radonc.2021.04.026.
Lien PubMed

[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]. Tougeron D, Seitz-Polski B, Hentzien M, Bani-Sadr F, Bourhis J, Ducreux M, Gaujoux S, Gorphe P, Guiu B, Hardy-Bessard AC, Hoang Xuan K, Huguet F, Lecomte T, Lièvre A, Louvet C, Maggiori L, Mariani P, Michel P, Servettaz A, Thariat J, Westeel V, Aparicio T, Blay JY, Bouché O; Thésaurus national de cancérologie digestive (TNCD); réseau de groupes coopérateurs en oncologie (GCO); Fédération nationale des centres de lutte contre le cancer (UNICANCER); association de chirurgie hépato-bilio-pancréatique et transplantation (ACHBT); association de recherche sur les cancers gynecologiques-groupes d’investigateurs nationaux pour l’étude des cancers ovariens et du sein (ARCAGY-GINECO); Fédération francophone de cancérologie digestive (FFCD), groupe coopérateur multidisciplinaire en oncologie (GERCOR), groupe d’oncologie radiothérapie tête et cou-intergroupe ORL (GORTEC-Intergroupe ORL); intergroupe francophone de cancérologie thoracique (IFCT); intergroupe coopérateur de neuro-oncologie association des neuro-oncologues d’expression française (IGCNO-ANOCEF); Société française de chirurgie digestive (SFCD); Société française d’endoscopie digestive (SFED); Société française de radiothérapie oncologique (SFRO); Société française de radiologie (SFR); Société nationale française de colo-proctologie (SNFCP); Société nationale française de gastroentérologie (SNFGE). Bull Cancer. 2021 Apr 12:S0007-4551(21)00137-5.
Lien PubMed

Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes. Frédéric Peyrade, Christian Borel, Amaury Daste, Caroline Even, Esma Saada-Bouzid, Joël Guigay. Curr Opin Oncol. 2021 May 1;33(3):160-167. doi: 10.1097/CCO.0000000000000738.
Lien PubMed

Radiotherapy of sinonasal cancers. Larnaudie A, Delaby N, Marcy PY, Leleu T, Costes-Martineau V, Vergez S, de Gabory L, Quintyn JC, Doré M, Pointreau Y, Thariat J. Cancer Radiother. 2021 Dec 13:S1278-3218(21)00271-7.
Lien PubMed

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. PMID: 32758455.
Lien PubMed

Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Batailhou N, Thariat J, Guigay J, Bourhis J. Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24. PMID: 33125944.
Lien PubMed

A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. Biau J, Thivat E, Millardet C, Saroul N, Pham-Dang N, Molnar I, Pereira B, Durando X, Bourhis J, Lapeyre M. BMC Cancer. 2020 Aug 5;20(1):730
Lien PubMed

Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. Janoray G, Pointreau Y, Alfonsi M, Sire C, Geoffrois L, de Raucourt D, Bardet E, Calais MH, Garaud P, Calais G. Eur J Cancer. 2020 Jul;133:86-93.
Lien PubMed

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. Tao Y, Auperin A, Blanchard P, Alfonsi M, Sun XS, Rives M, Pointreau Y, Castelli J, Graff P, Wong Hee Kam S, Thariat J, Veresezan O, Heymann S, Renard-Oldrini S, Lafond C, Cornely A, Casiraghi O, Boisselier P, Lapeyre M, Biau J, Bourhis J. Radiother Oncol. 2020 May 15;150:18-25.
Lien PubMed

A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. Atallah S, Casiraghi O, Fakhry N, Wassef M, Uro-Coste E, Espitalier F, Sudaka A, Kaminsky MC, Dakpe S, Digue L, Bouchain O, Morinière S, Hourseau M, Bertolus C, Jegoux F, Thariat J, Calugaru V, Schultz P, Philouze P, Mauvais O, Righini CA, Badoual C, Saroul N, Goujon JM, Marie JP, Taouachi R, Brenet E, Aupérin A, Baujat B. Eur J Cancer. 2020 May;130:241-249.
Lien PubMed

Management of cN0 low-grade mucoepidermoid carcinomas of salivary glands: Prospective multicentre study of 152 cases of the French Network of Rare Head and Neck Tumors (REFCOR). Saloner Dahan L, Giorgi R, Garrel R, Le Taillandier de Gabory L, Costes-Martineau V, Herman P, Poissonnet G, Mauvais O, Malard O, Vergez S, Uro-Coste E, Barry B, Bach C, Chevalier D, Mouawad F, Merol JC, Bastit V, Thariat J, Gilain L, Dufour X, Righini CA, Dessi P, Michel J, Radulesco T, Even C, Baujat B, Fakhry N. Clin Otolaryngol. 2020 Nov;45(6):926-931.
Lien PubMed

Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study. Atallah S, Moya-Plana A, Malard O, Poissonnet G, Fakhry N, Bettoni J, Gallet P, Ransy P, Vergez S, De Gabory L, Evrard D, Lesnik M, Philouze P, Bertolus C, Schultz P, Morinière S, Bastit V, Righini CA, Mirghani H, Jegoux F, Mauvais O, Biau J, Dufour X, Bon-Mardion N, Brenet E, Verillaud B, Baujat B. Eur J Cancer. 2020 May;130:250-258.
Lien PubMed

Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Haitham Mirghani, Carine Bellera, Jessy Delaye, Gilles Dolivet , Nicolas Fakhry, Alexandre Bozec, Renaud Garrel, Olivier Malard, Franck Jegoux, Philippe Maingon, Jérome Sarini, Georges Noel, Suzy Duflo, Stéphane Temam, Jean-Louis Lefebvre, Valérie Costes-Martineau. Cancer Epidemiol. 2019 Aug;61:89-94. doi: 10.1016/j.canep.2019.05.007.
Lien PubMed

Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. Moya-Plana A, Aupérin A, Obongo R, Baglin A, Ferrand FR, Baujat B, Saroul N, Casiraghi O, Vergez S, Herman P, Janot F, Thariat J, Vérillaud B, de Gabory L; REFCOR members. Eur J Cancer. 2019 Dec;123:1-10.
Lien PubMed

Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares. Villepelet A, Lefèvre M, Verillaud B, Janot F, Garrel R, Vergez S, Bertolus C, Malard O, de Gabory L, Mauvais O, Baujat B; REFCOR members. Head Neck. 2019 Mar;41(3):584-591.
Lien PubMed

Surgery or Radiotherapy of the Primary Tumor in T1-2 Head and Neck Squamous Cell Carcinoma with Resectable N3 Nodes: A Multicenter GETTEC Study. Carsuzaa F, Thariat J, Gorphe P, Righini C, Cosmidis A, Thureau S, Roge M, De Mones E, Servagi-Vernat S, Tonnerre D, Morinière S, Dugas A, Malard O, Pasquier F, Vergez S, Salleron J, Dufour X. Ann Surg Oncol. 2019 Oct;26(11):3673-3680.
Lien PubMed

Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. Moya-Plana A, Aupérin A, Obongo R, Baglin A, Ferrand FR, Baujat B, Saroul N, Casiraghi O, Vergez S, Herman P, Janot F, Thariat J, Vérillaud B, de Gabory L; REFCOR members. Eur J Cancer. 2019 Oct 24;123:1-10.
Lien PubMed

Treatment of inoperable elderly head and neck cancer patients. Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C. Curr Opin Oncol. 2019 May;31(3):152-159. doi: 10.1097/CCO.0000000000000526
Lien PubMed

Diagnostic and treatment pitfalls and guidelines for variants of squamous cell carcinomas of the head and neck: on behalf of the REFCOR. Thariat J, Hourseau M, Baglin AC, Digue L, Vulquin N, Badoual C, Baujat B, Janot F, Ferrand FR, Barry B. Bull Cancer. 2019 Apr;106(4):395-403.
Lien PubMed

Head and neck cancer during pregnancy. Le Guevelou J, Lebars S, Kammerer E, de Gabory L, Vergez S, Janot F, Baujat B, Righini C, Jegoux F, Dufour X, Merol JC, Mauvais O, Lasne-Cardon A, Selleret L, Thariat J. Head Neck. 2019 Oct;41(10):3719-3732.
Lien PubMed